UBS maintains Insulet at Neutral, raises price target to $171 from $150
UBS kept its Neutral rating on Insulet but increased its price target to $171 from $150, suggesting a 9.5% upside from the last close. Recent analyst targets range from $167 to $200.
How this was made

The 30-second read
Why it matters
The upgrade may prompt short covering and new buying, modestly boosting the stock.
Market read
Analyst target raise is a modest catalyst for Insulet, offering a short‑term upside signal.
What to watch
Potential regulatory or reimbursement risks not reflected in the target.
Background
UBS analyst coverage on Insulet includes a new price target of $171, up 14% from the prior $150.
Ticker impact
UBS raised its price target on Insulet to $171 from $150, indicating a bullish view.
likely upward pressure as investors price in the higher target
Target increase reflects improved expectations and may attract buying interest.
Market effects
May lift sentiment in the medical device sector as analysts see growth potential.
Limited to US markets where Insulet trades.
Minimal global impact beyond sector peers.
Counterpoint
Target raise could be premature if upcoming earnings miss expectations.
Key entities
- companyInsulet Corp
Medical device maker specializing in insulin pumps.
- analystUBS
Investment bank providing research coverage on Insulet.
